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Abstract
Background: The target-controlled infusion-III (SLOG/TCI-III) system was derived from a model set up by the local
pediatric population for target control infusion of propofol.
Methods: The current study aimed at evaluating the difference between target concentrations of propofol and
performance, which was measured using the SLOG/TCI-III system in children. Thirty children fulfilling the I-II criteria
according to American Society of Anesthesiology were enrolled in the study. The target plasma concentration of
propofol was fed into the SLOG/TCI-III system and compared with the measured concentrations of propofol. Blood
samples were collected and analyzed by high performance liquid chromatography with fluorescence detector. The
performance error (PE) was determined for each measured blood propofol concentration. The performances of the
TCI-III system were determined by the median performance error (MDPE), the median absolute performance error
(MDAPE), and Wobble (the median absolute deviation of each PE from the MDPE), respectively.
Results: Concentration against target concentration showed good linear correlation: concentration = 1.3428 target
concentration - 0.2633 (r = 0.8667). The MDPE and MDAPE of the pediatric system were 10 and 22%, respectively,
and the median value for Wobble was 24%. MDPE and MDAPE were less than 15 and 30%, respectively.
Conclusions: The performance of TCI-III system seems to be in the accepted limits for clinical practice in children.
Keywords: Propofol, plasma concentration, high performance liquid chromatography, drug delivery system, pedia-
tric, evaluation
Introduction
The effectiveness and safety of pharmacokinetics and
pharmacodynamics of anesthetic drugs, such as propo-
fol, were studies in the pediatr i cp o p u l a t i o n .T h ea p p l i -
cation of target controlled infusion (TCI) has been
expanded to pediatric anesthetization and sedation dur-
ing surgery, as a functional pharmacokinetic model pri-
marily for propofol and Alfentanil. Clinical studies on
TCI of propofol for pediatric anesthetization have veri-
fied that factors such as ethnic group, body weight, and
age influence pharmacokinetic parameters, which can
vary greatly from those of adults [1-3]. The distribu-
tional volume of central compartments in pediatrics is
larger than the corresponding value in adults. As the
Diprifusor software was written based on adult para-
meters, Absalom et al. pointed out that the adult para-
meters of Marsh model might not be appropriate for
TCI of propofol in children [4]. This challenge was also
emphasized in TCI of propofol to children in pediatric
anesthetization [5].
“Paedfusor” was introduced as the first TCI system for
pediatric induction and maintenance of anesthesia, fol-
lowed by the analytic research on pharmacokinetic para-
meters of propofol in adults and children, associated with
age, body weight, samples, and drug administration
approach [6]. The difference in the pharmacokinetic
model of propofol for adults lies in the fact that the cen-
tral compartmental volume is expanded correspondingly
to the ratio of infantile ages by Paedfusor. The perfor-
mance of TCI for cardiac catheterization or selective car-
diac surgery was studied in 29 children between 1 and 15
years old using the Paedfusor system [6]. The median
performance error, median absolute performance error
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about 4 and 10%, respectively [6]. The degree of Wobble
was about 8%. In comparison to the acquired pediatric
values with “Diprifusor” for adults, these results are more
accurate and satisfactory in clinical effect. In China, the
current practice is the use of embedded TCI systems that
are either calibrated according to the adult pharmacoki-
netic parameters or according to western pediatric data.
The accuracy of such practice is still questionable, due
to a number of influencing factors such as ethnicity,
age, drug disposition and drug response. The SLOG/
TCI-III system is based on pharmacokinetic characteris-
tics derived for the local pediatric population. The presi-
dent study aimed at evaluating the quality analysis of
equivalence in the actual measured concentration and
the target concentration of propofol using the TCI-III in
p e d i a t r i cp a t i e n t sw i t hs u r g e r y .W eh o p eo u rp r e l i m i n -
ary results can attract the special attention to standar-
dize the performance and clinical application of the
pediatric model for target-controlled infusion of propo-
fol. The present study also indicates needs of investiga-
tions to explore cellular and molecular mechanisms and
system-specific biomarkers as a bed to bench approach
by integrating clinical bioinformatics [7-9].
Materials and methods
Primary equipments
Waters high performance liquid-phase chromatography
with the inclusive of constant flow pump of model 510,
fluorescence testing instrument of 2475, and spectrum
workstation of Millennium2010, and chromatographic
column Zorbax Eclipse C18 with 250 mm × 4.6 mm, 5
μm, were used. HP 78352 multi-function monitor (Qin-
dao subsection of HP company, China) and monitoring
instrument for bi-spectral index (Covidien, Ireland) were
used. Injection pump of model TCI-III with included
parameters of pediatric propofol was purchased from
the Beijing SLOG/TCI-III Technology Development Co.,
(China).
Primary test agents
The testing agents were used, e.g. propofol (99.9% pur-
ity, Astrazeneca, UK), thymol (batch no. 100508-2003.1,
National Institute for the Control of Pharmaceutical and
Biological Products, China), acetonitrile (high perfor-
mance liquid chromatography grade, AS-1122, TEDIA,
USA), methanol (high performance liquid chromatogra-
phy grade, MS-1922, TEDIA), glacial acetic acid
(T2004D32G, Sinopharm Chemical Reagent Co., Shang-
hai, China), 20% trichloroacetic acid & 20% perchlorate,
blank plasma (plasma of healthy subjects, provided by
Shanghai Ruijin Hospital, China), sodium lactate &
Ringer’s solution (2007060102, HuaYu Pharmaceutical
Co., Wuxi, China), injection of propofol (Diprivan)
(Imported drug registration H20030427, FA283,
Imported drug registration H20030481, FB908, Astraze-
neca, Italy), injection of midazolam (20061204, Jiangsu
Nhwa Pharma. Co., Jiangsu, China), ketamine hydro-
chloride (KH070404, Jiangsu Heng Rui Medicine Co.,
Jiangsu, China), injection of vecuronium (208609, Nanj-
ing Organon Pharmaceutical Co., Nanjing, China), iso-
flurane (535335U, Shanghai Yapei Pharmaceutical,
Shanghai, China), and sevoflurane (070530, Jiangsu
Heng Rui Medicine Co.).
Research subjects
Thirty pediatric patients above 12 kg for elective surgery
of grades I and II, in accordance to the qualifications of
American Anesthetic Association, were recruited,
including 12 boys and 18 girls with body weights
between 12 and 34 kg, ages ranging from 1 to 7.7 years,
and heights between 78 and 138 cm, respectively. The
duration of surgery was between 114 and 490 minutes
(197 ± 82 min). The study was approved by the Institu-
tional Review Board prior to the subjects being enrolled
and pre-operative informed consent was obtained from
parents of all the participants. The exclusion criteria
were the following: allergic to propofol, history of anes-
thetic complications, liver and kidney impairment,
hematological disease, metabolic disorders, inherent tra-
cheal problem, inability to cooperate for questionnaires,
anticipated hemodynamic instability during surgery, sub-
jects requiring specific or large quantity of infusion, and
expected shorter duration of surgery (less than 1 hour).
Drug administration
Pre-operative preparations included routine fasting
before surgery and 10 minutes of resting in supine posi-
tion after entering the operation room. Vital parameters
were measured using the hypertension multi-function
monitor, and the degree of sedation was monitored. The
unilateral peripheral vein was used for injection of
sodium lactate and Ringer’s solution at 10-15 mL·kg
-1·h
-
1. Anesthetics was induced and maintained with the
continuous venous infusion of propofol at 1.0 ug·mL
-1,
followed by midazolam at 0.01 mg·kg
-1, ketamine hydro-
chloride at 2 mg·kg
-1, and vecuronium at 2 mg·kg
-1.
After 5 minutes, tracheal intubation and intermittent
ventilation under positive pr e s s u r ew e r ep e r f o r m e dt o
maintain the carbon dioxide partial pressure at 35 to 45
mmHg. For anesthesia maintenance on basis of the age
and body weight, the TCI-III system for propofol
(Pediatric mode) was set with targeted plasma concen-
tration of 1 to 4 μg·ml
-1 for controlled infusion. Dinitro-
gen oxide-isoflurane- oxygen or both-sevoflurane, was
used for anesthetic maintenance. For the postoperative
monitoring, anesthetic gas was shut off after suturing
during surgery and the TCI pump was adjusted to
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expired concentration reached zero.
Observational indices
Observational indices were selected on basis of measure-
ments related to the general life information, adverse
reactions, and drug-associated effects. During the presi-
dent study the age, body weight, height, sex, admission
number, anesthetic drug combination, surgical proce-
dure, and demographic characteristics of patients were
recorded. Vitals signs were observed, including electro-
cardiography, oxygen saturation, non-invasive blood
pressure, electrocardiograph - bispectral index, target
concentration of propofol at each time point of blood
sampling, total dosage of propofol for anesthetization,
total time of propofol usage, and adverse reactions,
including brachycardia, heart rate < 50 bpm, low blood
pressure systolic pressure < 85 mmHg, or systolic pres-
sure lower than 30% or more of the basal value.
Collection of plasma samples
The initial target concentration for sedation with propo-
fol under TCI was 1.0 μg/ml
-1 and 2 to 4 target concen-
trations were set accordingly to surgical status during
anesthetization. When a target concentration shown by
the equipment remained constant 5, 10, 20, and 30 min-
utes after the adjustment, 1.5 to 2 ml of peripheral
venous blood sample was collected from another site
and placed in the tube with anti-coagulant EDTA. Sam-
ples were stored in 4°C refrigerator after mixing. Within
2 hours, it was centrifuged under room temperature at
the rotation speed of 400 × g for 10 minutes. Plasma
was stored in -80°C till further analysis.
Handling and measuring of plasma samples
The plasma concentration of propofol was measured
with high-performance liquid-phase chromatography
and fluorescent method using Thymol as an internal
standard and acetonitrile as the protein precipitator.
The analytical column used was Zorbax Eclipse C18
(250 mm × 4.6 mm, 5 μm) at a column temperature of
20-24°C. The mobile phase consisted of acetonitrile and
water (70:30) at pH 4.0 adjusted with glacial acetic acid
and was pumped at a flow-rate of 1.0 mL· min
-1.T h e
excitation wavelength was set at 276 nm and emission
at 310 nm. 100 uL of plasma sample was accurately
acquired and placed in the tube. 200 uL of acetonitrile
with internal standard was added as protein precipitator
before placing it on the vortex mixer for 30 seconds and
then centrifuged for 10 minutes at 1300 × g.1 0u L
supernatant was obtained and loaded into the high-per-
formance liquid-phase chromatography and fluorescent
instrument for measuring plasma concentration of pro-
pofol. The assessment results for the methodology
showed the following: the linear range of measurement
fell between 19 and 9630 ng·mL
-1 (r = 0.9999, n =8 )
and the lowest measuring concentration was 0.38
ng·mL
-1. The recovery rate of concentrations at 39, 770,
and 7704 ng·mL
-1 were 100, 103 and 101 after storing 6
and 24 h in room temperature, freezing for 30 days and
exchanging between freezing and thawing 3 times (n =
5). The variable coefficient of daily precision was ≤1.0%,
and the variable coefficient between dates was ≤3.75%.
Intrinsic compounds and preoperative or surgical medi-
cines did not affect the measurement of propofol con-
centration in the plasma of healthy subjects.
Data processing and statistical analysis
Data were analyzed using SPSS 11.5 software and pre-
sented as mean ± standard deviation. The performance
assessment of TCI system was performed as described
by Varvel et al. [10]. The variance between the actual
measured drug concentration in plasma and the target
concentration at corresponding time point was pre-
sented in percentage of performance error (PE): PE%=
(concentrationij - target concentrationij )/target con-
centrationij × 100%, reflecting the precision of the
measuring system. The bias of system was presented
by the medium value of PE (MDPE): MDPEi = median
{PEij; j = 1,..., Ni }, describing whether the performance
of the system was lower or higher than expected. The
precision of the system was presented by the medium
value of absolute value of performance error
(MDAPE): MDAPEi = median {|PE|ij, j = 1,..., Ni },
indicating the inaccuracy of the control system. The
degree of Wobble in the system was presented by the
medium value of absolute deviation: Wobble = median
{|PEij -MDPEij|, j = 1,..., Ni }, representing the variabil-
ity of performance error.
Performance assessment of target control infusion system
for propofol
Currently, most references were used including bias
(MDPE), precision (MDAPE), and the degree of Wobble
in the system as assessment indices for the performance
of TCI system. It is generally believed that MDPE <15%
and MDAPE<30% indicated satisfaction in clinical appli-
cation [10-12].
Results
Blood sampling and results of analysis by high perfor-
mance liquid chromatography are shown in Table 1.
Comparative analysis was performed on the targeted
drug concentrations in plasma after drug administration
by TCI-III “Pediatric” system and the actual measured
drug concentrations in 180 collected blood samples. Lin-
ear regression was drawn for concentration and target
concentration, where the linear equation turned out to
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(r = 0.8667) (Figure 1A). It suggested a close linear
relationship between concentration and target concen-
tration. Linear regression was drawn again for target
concentration and performance error (PE) and the equa-
tion was calculated as: PE = 0.0726 target concentration
+ 0.0291(r = 0.1980) (Figure 1B).
180 blood samples were analyzed accordingly to age
differences: 1<yr<3 and 3<yr<8 (Table 2, Figure 2, 3).
The values of MDPE, MDAPE, and Wobble of children
between 1 and 8 years old were 10%, 22%, and 24%,
respectively. The values of MDPE, MDAPE, and Wobble
of children between 1 and 3 years old were 15%, 17%,
and 14%, respectively. The values of MDPE, MDAPE,
and Wobble of children between 3 and 8 years old were
9%, 25%, and 28%, respectively. The values of MDPEs at
all age groups using TCI-III “Pediatric” system were less
than 15% and MDAPEs were less than 30%, of which all
fell within acceptable clinical range.
Discussion
Pharmacokinetic parameterso fp r o p o f o lv a r yw i t ha g e ,
sex, body weight, disease condition, and usage of conco-
mitant drug. The central compartment is larger in
volume and the clearance rate is higher in children. For
children of age 3 or above, the distributional volume
and clearance rate require adjustment according to the
body weight. For children under 3-years-old, pharmaco-
kinetic parameters correspond positively with body
weight, in which the clearance rates of the central com-
partment and entire body are much higher than those
of older children [13,14]. Therefore, the present study
investigated alterations in further subdivided groups
betwe,en >3-years-old and <3-years-old.
The performance of the TCI system depends primarily
on the degree of closeness achieved between target con-
centration and concentration in the plasma. However,
TCI system may hardly maintain the equilibrium
between measured concentration and the target concen-
tration, due to the variations between individuals or
groups. The target concentration could be adjusted
according to clinical need, if the measured and target
concentrations were in parallel relationship. The range
of measured concentrations of propofol was wider. The
performance error demonstrated a positive relationship
Table 1 The relationship between target concentration
and actual measured concentration (¯ x ± SD)
Target Conc.
(μg·mL
-1)
Measured Conc.
(μg·mL
-1)
Performance error(PE)
(%)
0.51 0.91 0.79
0.52 0.52 0.00
0.61 0.84 0.37
0.69 1.38 1.01
0.71 0.73 0.03
0.72 0.64 -0.12
0.73 0.6 ± 0.24 (n = 2) -17.72 ± 32.81(n = 2)
0.75 0.67 -0.11
0.78 1.04 0.33
0.81 1.23 0.52
0.82 1.07 ± 0.3 (n = 2) 31.06 ± 36.68(n = 2)
0.84 0.88 0.04
0.87 0.86 -0.01
0.88 1.57 0.78
0.91 1.13 ± 0.04 (n = 2) 0.24 ± 0.004 (n = 2)
0.98 0.86 -0.12
1 1.02 ± 0.38(n = 52) 1.67 ± 37.84(n = 52)
1.01 1.02 0.01
1.02 1.66 0.63
1.17 0.87 -0.26
1.32 1.04 2.5-0.21
1.5 1.67 ± 0.65(n = 4) 11.35 ± 43.62(n = 4)
2 2.53 ± 0.63(n = 35) 26.62 ± 31.52(n = 35)
2.5 3.2 ± 0.69(n = 18) 27.83 ± 28.79(n = 18)
3 3.5 ± 1.07(n = 29) 16.82 ± 35.61(n = 29)
3.5 4.14 ± 1.04(n = 8) 18.17 ± 29.62(n = 8)
3.75 4.07 ± 1.48(n = 2) 8.53 ± 39.39(n = 2)
4 5.83 ± 1.66(n = 9) 45.81 ± 41.54(n = 9)
Figure 1 Predicted concentrations of Propofol in 1<year< 8 by
SLOG TCI-III (Pediatric) system (Figure 1A), and performance
error (PE%) against the calculated concentrations in 1<year< 8
by SLOG TCI-III (Pediatric) system (Figure 1B).
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previous finding [15]. The MDPE of TCI-III Pediatric
system showed that the measured concentrations of pro-
pofol in blood were generally higher than the target. It
implies that the TCI-III pediatric system underestimated
the drug concentration in blood. Clinical application of
those TCI-III systems could cause a deeper anesthesia
than expected, leading to increased hemodynamic fluc-
tuation and other risks of excess anesthesia.
The present study is the initial one to evaluate the
application of SLOG TCI-III system in pediatric surgery.
Results showed that MDPEs and MDAPEs at all age
groups of children were within normal range, suggesting
that the TCI-III system could effectively achieve the tar-
get goal in the selected patients. The degree of Wobble
in the system was slightly higher in children of 1-3 and
3-8 years old, respectively, probably due to the wide var-
iation in pharmacokinetic characteristics of propofol in
children.
The evaluation of SLOG/TCI-III system on target-
controlled infusion of propofol has been performed in
clinic, of which measurements were clinical parameters.
For example, the simultaneous closed-loop anesthesia
control system was clinically evaluated [16]. The effect
of propofol and remifentanil combinations was modeled
and compared on basis of clinical measurements [17,18].
The present study indicates the needs of system-specific
biomarkers by translational medicine. Dr Marincola
recently emphasized the importance and need to
increase the understanding of human pathophysiology
and use surrogate biomarkers to early assess efficacy of
intervention [19]. The great challenge is how to translate
Table 2 The performance status of SLOG/TCI-III (Pediatric) system in age groups
Age group 1<year< 3 3<year < 8 1<year< 8
Concentration(Y)and Target concentration(X) Linear Regression: y = 1.2711 × - 0.1097
(r = 0.9220)
y = 1.362 × - 0.3044
(r = 0.8556)
y = 1.3428 × - 0.2633
(r = 0.8667)
PE(Y) Target concentration (X)
Linear Regression:
y = 0.0476 × + 0.0867
(r = 0.1900)
y = 0.0843 × - 0.0001
(r = 0.2161)
y = 0.0726 × - 0.0291
(r = 0.1980)
MDPE (%) 14.89 8.75 9.58
MDAPE (%) 16.69 24.58 21.77
Wobble (%) 14.25 27.69 23.62
Abbreviations: PE: performance error; MDPE: medium value of performance error; MDAPE: the medium value of absolute value of performance error; Wobble:
medium value of absolute deviation.
Figure 2 Predicted concentrations of Propofol in 1<year< 3 by
SLOG TCI-III(Pediatric)system (Figure 2A), and performance
error (PE%) against the calculated concentrations in 1<year< 3
by SLOG TCI-III (Pediatric) system (Figure 2B).
Figure 3 Predicted concentrations of Propofol in 3<year < 8 by
SLOG TCI-III (Pediatric) system (Figure 3A), and performance
error (PE%) against the calculated concentrations in 3<year < 8
by SLOG TCI-III (Pediatric) system (Figure 3B).
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“bench” by using advanced biotechnologies [20]. Clinical
and translational science provides a new approach to
develop and validate disease-specific or intervention-
associated biomarkers [21-23]. It is possible to integrate
clinical information with bioinformatics driven from
plasma proteomics and discover new drug-specific bio-
markers for the further evaluation [24-26].
In conclusion, clinical application of the target con-
centration could be appropriately adjusted by the
anesthesiologist, according to the need of degree of
anesthetization, in order to overcome the differences in
pharmacokinetics and pharmacodynamics between indi-
viduals. There is a need to further evaluate the perfor-
mance of TCI-III in a large population of patients. The
performance of TCI-III system seems to be within the
accepted limits for clinical practice in children. It could
make the TCI-III system much safer and convenient to
use.
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